The US Federal Trade Commission is "fully prepared" to bring forward cases after issuing hundreds of penalty offense notices in April regarding health claims substantiation, and it is likely to seek injunctive and monetary relief, said Samuel Levine, director of the FTC’s Bureau of Consumer Protection, at the National Advertising Division’s annual conference in Philadelphia.
The US Federal Trade Commission is well-positioned to take legal action as necessary against the nearly 700 consumer product firms that received notices of penalty offense (NPO) earlier this year related to health claims substantiation, according to Samuel Levine, director of the FTC’s Bureau of Consumer Protection.
“We’ve already followed up on this in some of our investigative work; we’re fully prepared to bring those cases
NAD and NARB track their decisions on support for ad claims with Federal Trade Commission policies, including the requirement of RCTs to support health claims for supplements, a standard the industry argues is required for drug claims and shouldn’t be applied for dietary ingredients.
Swedish producer of antioxidant astaxanthin AstaReal has expanded its product offering with cardiovascular health focused-brand Kyolic.
Agreement with Seoul-based health and wellness player TopHealth will see the roll out of ProBiotix' cholesterol-lowering probiotics in South Korea.
Vitawell seeking to empower consumers left confused by the vast array of dietary supplements available to them in the UK.
C&D reports Q1 net sales dropped 2.4% to $1.48bn, below its guidance for around 1% growth. Its brands’ sales at retail and market share grew in the quarter, but “experienced slowing category growth in the US market” as retailers reduced inventory levels.
Herbalife expects little impact from increased tariffs on imports from China but strong boosts from acquiring Pro2col Health and Pruvit Ventures Inc. and 51% ownership of Link BioSciences.
Private equity firm CD&R takes control of Opella while Sanofi retains a sizeable stake and nets €10bn.
